Avalo Therapeutics (AVTX) EBITDA (2014 - 2026)

Avalo Therapeutics has reported EBITDA for 13 years, with the latest figure at -$19.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 49.85% year-over-year to -$19.7 million; the trailing twelve-month figure through Mar 2026 stood at -$84.7 million (down 216.07% YoY), and the FY2025 full-year result was -$78.2 million, down 122.58% from the prior year.
• EBITDA for Q1 2026 stood at -$19.7 million, down from -$13.7 million in the prior quarter.
• The five-year high for EBITDA was $98.5 million in Q2 2024, with the low at -$121.3 million in Q1 2024.
• Historically, EBITDA has averaged -$12.0 million across 5 years, with a median of -$13.0 million in 2022.
• The largest YoY upside for EBITDA was 1301.79% in 2024 against a maximum downside of 1118.38% in 2024.
• Avalo Therapeutics' EBITDA stood at -$8.9 million in 2022, then advanced by 13.52% to -$7.7 million in 2023, then plunged by 361.47% to -$35.3 million in 2024, then soared by 61.25% to -$13.7 million in 2025, then sank by 43.9% to -$19.7 million in 2026.
• The last three EBITDA figures came in at -$19.7 million (Q1 2026), -$13.7 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.